{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:35:39Z","timestamp":1755794139160,"version":"3.44.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To describe a novel case of progressive fundus hypopigmentation and choroidal thinning associated with tebentafusp monotherapy for metastatic uveal melanoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Observational case report and review of the literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 69-year-old male was diagnosed with a choroidal melanoma, measuring 13.3\u00a0mm in diameter and 5.8\u00a0mm in thickness, in the left eye. Seven years after iodine-125 plaque brachytherapy, systemic imaging identified a solitary liver metastasis, which was laparoscopically resected. About one year later, two new liver metastases were detected. The patient was HLA-A*02:01 positive and started on tebentafusp. Except for transient fever, rash, and pruritus after the first cycles, the therapy was well tolerated. Fourteen months after initiation of tebentafusp, fundoscopy revealed marked hypopigmentation of both fundi and depigmentation of the regressed tumour in left eye. There were no signs of intraocular inflammation in either eye. Upon retrospective review of fundus photographs taken from baseline, the progressive fundus hypopigmentation and depigmentation of the tumour remnants first appeared after the initiation of immunotherapy. A corresponding evaluation of the optical coherence tomography scans of the previously untreated right eye revealed a significant reduction in central choroidal thickness over the same period. Full-field electroretinography demonstrated normal responses in the right eye and attenuated responses in the left eye. Screening for paraneoplastic antibodies was negative. During treatment, he also developed poliosis of the eyebrows and cilia, along with depigmented skin macules and patches. At the last visit, 11\u00a0years after the initial diagnosis and 26\u00a0months after starting tebentafusp, a repeat CT confirmed stable liver metastases with no new lesions. Both fundi appeared hypopigmented, and best corrected visual acuity was 1.0 in the right eye and hand movements in the left eye.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Tebentafusp therapy can lead to diffuse fundus hypopigmentation and choroidal thinning, similar to what has been reported after immune checkpoint inhibition. The progressive choroidal hypopigmentation, without evidence of associated intraocular inflammation, indicates that glycoprotein 100, the target antigen of tebentafusp, is also expressed by normal choroidal melanocytes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12886-025-04274-7","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:48:29Z","timestamp":1755262109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fundus hypopigmentation and choroidal thinning associated with tebentafusp therapy: report of a case and literature review"],"prefix":"10.1186","volume":"25","author":[{"given":"J\u00f8rgen","family":"Krohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liv Iren Hansen","family":"Vinnem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragnhild Wivestad","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oddbj\u00f8rn","family":"Straume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"4274_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46906-4","volume":"15","author":"S Leonard-Murali","year":"2024","unstructured":"Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, et al. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024;15(1): 2863. https:\/\/doi.org\/10.1038\/s41467-024-46906-4.","journal-title":"Nat Commun"},{"issue":"8","key":"4274_CR2","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"issue":"1","key":"4274_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol. 2023;7(1):41. https:\/\/doi.org\/10.1038\/s41698-023-00380-1.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"4274_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070971","volume":"11","author":"BE Damato","year":"2019","unstructured":"Damato BE, Dukes J, Goodall H, Carvajal RD. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 2019;11(7): 971. https:\/\/doi.org\/10.3390\/cancers11070971.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"4274_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"24","key":"4274_CR6","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"issue":"6","key":"4274_CR7","doi-asserted-by":"publisher","first-page":"e009028","DOI":"10.1136\/jitc-2024-009028","volume":"12","author":"JJ Sacco","year":"2024","unstructured":"Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, et al. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024;12(6):e009028. https:\/\/doi.org\/10.1136\/jitc-2024-009028.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"4274_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158030","volume":"22","author":"H Bareke","year":"2021","unstructured":"Bareke H, Juanes-Velasco P, Landeira-Vi\u00f1uela A, Hernandez AP, Cruz JJ, Bellido L, et al. Autoimmune responses in oncology: causes and significance. Int J Mol Sci. 2021;22(15): 8030. https:\/\/doi.org\/10.3390\/ijms22158030.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4274_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4274_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jid.2024.03.048","volume":"145","author":"JC Hassel","year":"2025","unstructured":"Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, et al. Tebentafusp induces a T-cell-driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J Invest Dermatol. 2025;145(3):559-72.e9. https:\/\/doi.org\/10.1016\/j.jid.2024.03.048.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"4274_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756.","journal-title":"J Clin Oncol"},{"issue":"13","key":"4274_CR12","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"6","key":"4274_CR13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063\u201378. https:\/\/doi.org\/10.1097\/IAE.0000000000002181.","journal-title":"Retina"},{"issue":"1","key":"4274_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","volume":"13","author":"A Martens","year":"2023","unstructured":"Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023;13(1):5. https:\/\/doi.org\/10.1186\/s12348-022-00321-2.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"4274_CR15","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1111\/aos.14237","volume":"98","author":"J Krohn","year":"2020","unstructured":"Krohn J, Hanken G, Herlofsen O. Choroidal naevus regression associated with PD-1 inhibitor monotherapy for metastatic cutaneous malignant melanoma. Acta Ophthalmol. 2020;98(2):e262-4. https:\/\/doi.org\/10.1111\/aos.14237.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"4274_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","volume":"105","author":"BH Fortes","year":"2021","unstructured":"Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol. 2021;105(9):1263\u201371. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316970.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"4274_CR17","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221. https:\/\/doi.org\/10.1371\/journal.pone.0160221.","journal-title":"PLoS One"},{"issue":"1","key":"4274_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","volume":"30","author":"D Bomze","year":"2022","unstructured":"Bomze D, Meirson T, Hasan Ali O, Goldman A, Flatz L, Habot-Wilner Z. Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm. 2022;30(1):191\u20137. https:\/\/doi.org\/10.1080\/09273948.2020.1773867.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"4274_CR19","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/j.jcjo.2024.08.003","volume":"60","author":"J Andoh","year":"2025","unstructured":"Andoh J, Thangamathesvaran L, Arevalo JF. Exudative subretinal fluid associated with tebentafusp immunotherapy. Can J Ophthalmol. 2025;60(1):e170\u20133. https:\/\/doi.org\/10.1016\/j.jcjo.2024.08.003.","journal-title":"Can J Ophthalmol"},{"key":"4274_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/aes-23-3","volume":"8","author":"CH Choo","year":"2023","unstructured":"Choo CH, Acharya NR, Shantha JG. Comprehensive and updated review on the diagnosis and treatment of Vogt-Koyanagi-Harada disease. Ann Eye Sci. 2023;8:4. https:\/\/doi.org\/10.21037\/aes-23-3.","journal-title":"Ann Eye Sci."},{"key":"4274_CR21","doi-asserted-by":"publisher","first-page":"9565205","DOI":"10.1155\/2023\/9565205","volume":"2023","author":"R Nagai","year":"2023","unstructured":"Nagai R, Yamamoto A, Yoshida A, Mikawa A. Outcome of nivolumab-induced vogt-koyanagi-harada disease-like uveitis in a patient managed without intravenous methylprednisolone therapy. Case Rep Ophthalmol Med. 2023;2023:9565205. https:\/\/doi.org\/10.1155\/2023\/9565205.","journal-title":"Case Rep Ophthalmol Med"},{"issue":"2","key":"4274_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09273948.2019.1577978","volume":"28","author":"MM Sun","year":"2020","unstructured":"Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ, Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2020;28(2):217\u201327. https:\/\/doi.org\/10.1080\/09273948.2019.1577978.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"4274_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","volume":"6","author":"RK Wong","year":"2012","unstructured":"Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012;6(4):423\u20136. https:\/\/doi.org\/10.1097\/ICB.0b013e31824f7130.","journal-title":"Retin Cases Brief Rep"},{"issue":"8","key":"4274_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/CJI.0000000000000476","volume":"46","author":"Y Huang","year":"2023","unstructured":"Huang Y, Khan F, Saraiya NV, Punjabi OS, Gulati V, Erickson AR, Yeh S. Vogt-koyanagi-harada-like syndrome induced by checkpoint inhibitor cemiplimab. J Immunother. 2023;46(8):295\u20138. https:\/\/doi.org\/10.1097\/CJI.0000000000000476.","journal-title":"J Immunother"},{"issue":"1","key":"4274_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12886-020-01519-5","volume":"20","author":"R Kikuchi","year":"2020","unstructured":"Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol. 2020;20(1):252. https:\/\/doi.org\/10.1186\/s12886-020-01519-5.","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"4274_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaophthalmol.2019.0970","volume":"137","author":"R Sophie","year":"2019","unstructured":"Sophie R, Moses GM, Hwang ES, Kim JE. Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with nivolumab. JAMA Ophthalmol. 2019;137(7):851\u20133. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.0970.","journal-title":"JAMA Ophthalmol"},{"key":"4274_CR27","doi-asserted-by":"publisher","first-page":"100799","DOI":"10.1016\/j.ajoc.2020.100799","volume":"19","author":"J Canestraro","year":"2020","unstructured":"Canestraro J, Jaben KA, Wolchok JD, Abramson DH, Francis JH. Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. Am J Ophthalmol Case Rep. 2020;19:100799. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100799.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"4274_CR28","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1097\/IAE.0000000000003467","volume":"42","author":"W Foulsham","year":"2022","unstructured":"Foulsham W, Abramson DH, Francis JH. choroidal nevus regression in the setting of checkpoint inhibition immunotherapy. Retina. 2022;42(5):e25\u20136. https:\/\/doi.org\/10.1097\/IAE.0000000000003467.","journal-title":"Retina"},{"key":"4274_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/ijo.IJO_724_21","volume":"2","author":"KG Chatzicharalampous","year":"2022","unstructured":"Chatzicharalampous KG, Barakos K, Papantoniou D, Kissopoulou A. Disappearance of choroidal nevi pigmentation following nivolumab treatment. Indian J Ophthalmol Case Rep. 2022;2:175\u20136. https:\/\/doi.org\/10.4103\/ijo.IJO_724_21.","journal-title":"Indian J Ophthalmol Case Rep"},{"issue":"1","key":"4274_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000535745","volume":"17","author":"CC Cotton","year":"2024","unstructured":"Cotton CC, Chandrabhatla AS, Higgins ML, Shildkrot Y. Bilateral vitiligo-like depigmentation of choroid and retinal pigment epithelium associated with ipilimumab-nivolumab therapy for metastatic cutaneous melanoma. Case Rep Oncol. 2024;17(1):122\u20137. https:\/\/doi.org\/10.1159\/000535745.","journal-title":"Case Rep Oncol"},{"key":"4274_CR31","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.ajoc.2024.102021","volume":"34","author":"JH Francis","year":"2024","unstructured":"Francis JH, Barker CA, Canestraro J, Abramson DH, Shoushtari AN. Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors. Am J Ophthalmol Case Rep. 2024;34:102021. https:\/\/doi.org\/10.1016\/j.ajoc.2024.102021.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"4274_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/07357907.2022.2108827","volume":"40","author":"S Kamat","year":"2022","unstructured":"Kamat S, Patel J, Brown BR, Vyas A. Adverse events induced by nivolumab plus ipilimumab vs. nivolumab monotherapy among cancer patients: a systematic review and meta-analysis. Cancer Invest. 2022;40(9):777\u201388. https:\/\/doi.org\/10.1080\/07357907.2022.2108827.","journal-title":"Cancer Invest"},{"issue":"1","key":"4274_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"8","key":"4274_CR34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","volume":"13","author":"I Gkiozos","year":"2018","unstructured":"Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. 2018;13(8):1076\u201382. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.031.","journal-title":"J Thorac Oncol"},{"key":"4274_CR35","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.ajoc.2020.100652","volume":"18","author":"C Ung","year":"2020","unstructured":"Ung C, Gragoudas E. Checkpoint inhibitor-induced sarcoid choroidal granulomas. Am J Ophthalmol Case Rep. 2020;18:100652. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100652.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"8","key":"4274_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","volume":"20","author":"JE Lommerts","year":"2021","unstructured":"Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021;20(8):883\u20138. https:\/\/doi.org\/10.1080\/14740338.2021.1915279.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"4274_CR37","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/bjc.1998.646","volume":"78","author":"TJ de Vries","year":"1998","unstructured":"de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer. 1998;78(9):1156\u201361. https:\/\/doi.org\/10.1038\/bjc.1998.646.","journal-title":"Br J Cancer"},{"key":"4274_CR38","doi-asserted-by":"publisher","unstructured":"Casselman P, Jacob J, Schauwvlieghe PP. Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature. J Ophthalmic Inflamm Infect. 2023;13(1):16 https:\/\/doi.org\/10.1186\/s12348-023-00338-1","DOI":"10.1186\/s12348-023-00338-1"},{"issue":"9","key":"4274_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.eye.6701351","volume":"18","author":"JR Vingerling","year":"2004","unstructured":"Vingerling JR, Owens S, van der Meijden WI, Hoyng CB, Bird AC. Cutaneous vitiligo associated with choroidal hypopigmentation. Eye (Lond). 2004;18(9):939\u201340. https:\/\/doi.org\/10.1038\/sj.eye.6701351.","journal-title":"Eye (Lond)"},{"issue":"4","key":"4274_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/archopht.125.4.576","volume":"125","author":"AP Ciardella","year":"2007","unstructured":"Ciardella AP, Horsley MB, Brown DM. Hypopigmentary fundus changes seen with cutaneous vitiligo. Arch Ophthalmol. 2007;125(4):576. https:\/\/doi.org\/10.1001\/archopht.125.4.576.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"4274_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ajo.2008.12.008","volume":"147","author":"R Margolis","year":"2009","unstructured":"Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147(5):811\u20135. https:\/\/doi.org\/10.1016\/j.ajo.2008.12.008.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4274_CR42","doi-asserted-by":"publisher","first-page":"992","DOI":"10.5301\/ejo.5000189","volume":"22","author":"G Coscas","year":"2012","unstructured":"Coscas G, Zhou Q, Coscas F, Zucchiatti I, Rispoli M, Uzzan J, et al. Choroid thickness measurement with RTVue optical coherence tomography in emmetropic eyes, mildly myopic eyes, and highly myopic eyes. Eur J Ophthalmol. 2012;22(6):992\u20131000. https:\/\/doi.org\/10.5301\/ejo.5000189.","journal-title":"Eur J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04274-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04274-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04274-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:48:30Z","timestamp":1755262110000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04274-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04274-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed the tenets of the Declaration of Helsinki. Regional Ethics Committee approval was not required for this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"464"}}